GLP-1 Receptor Agonists

Case study clinic: Multimorbidity & the ADA/EASD algorithm
Not started

Case study clinic: Multimorbidity & the ADA/EASD algorithm

0.5 hours

Interactive case study

Practice making decisions with the 2018 patient algorithm in this interactive case discussion. Featuring local-level commentary for France, Spain and Italy.

Case study clinic: Escalation to injections
Not started

Case study clinic: Escalation to injections

0.5 hours

Interactive case study

Continue to practice your decision-making when intensifying treatment beyond triple therapy. Featuring local commentary from France, Spain and Italy.

Case study clinic: Selecting between treatments & future perspectives
Not started

Case study clinic: Selecting between treatments & future perspectives

0.5 hours

Interactive case study

Consider clinical decision-making in a complex case and theoretical future scenarios. Featuring local commentary from France, Spain and Italy.

Decisions and considerations in T2D: GLP-1 RAs in the ADA/EASD treatment algorithm
Not started

Decisions and considerations in T2D: GLP-1 RAs in the ADA/EASD treatment algorithm

1 hour

Digital symposium

The 2018 ADA/EASD guidelines have provided a  patient algorithm to simplify and revolutionise patient care, providing an individualised approach in a time-efficient manner. But how should this guidance be implemented in practice? How should you use the algorithm to make clinical decisions?

This 4-part digital symposium summarises new treatment directions and the considerations required in treating type 2 diabetes. You can complete this alone or together with colleagues using the symposium's discussion guide, available to download from the module information page.

An overview of GLP-1 analogues
Not started

An overview of GLP-1 analogues

1 hour

eLearning module

A comprehensive overview of GLP-1 receptor agonists, including mechanism of action, multifactorial effects and how to predict response to their use in type 2 diabetes.

Intensifying T2D treatment with a GLP-1 RA
Not started

Intensifying T2D treatment with a GLP-1 RA

1 hour

eLearning module

A summary of guideline recommendations in the use of GLP-1 analogues, including how to help patients manage gastrointestinal side effects.

Selecting between therapeutics: Advantages and considerations
Not started

Selecting between therapeutics: Advantages and considerations

1 hour

eLearning module

A comprehensive summary of relevant data across GLP-1RAs, SGLT2 inhibitors and DPP-4 inhibitors, complete with guidance on how to select between these.

Once-weekly injectables:  Within-class differences and their relevance in the real world
Not started

Once-weekly injectables: Within-class differences and their relevance in the real world

1 hour

eLearning module

A review of data surrounding once-weekly GLP-1 receptor agonists, including clinical trial data and how these apply to the real world.

Future perspectives: next-generation formulations of GLP-1 RAs
Not started

Future perspectives: next-generation formulations of GLP-1 RAs

1 hour 1 CME Credit

eLearning module

A summary of up-and-coming next generation GLP-1 RAs, clinical trial data associated with these and future perspectives on how they may impact practice. 

Funding information is available at the beginning of each activity. All content has been developed by Liberum IME in conjunction with an independent steering committee; financial supporters have had no influence on the content of this education.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries.Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu